Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia
DALLAS, TX (Jun 4, 2009) - An ongoing Phase Ib study of Memgen's cancer immune therapy, ISF35, has produced positive results, including a complete remission in the trial's first patient who had 17p deleted chronic lymphocytic leukemia (CLL).
The study, which is co-sponsored by the Leukemia & Lymphoma Society, assesses the ability of ISF35 to re-sensitize refractory and/or 17p deleted CLL to chemotherapy.
The University of California, San Diego (UCSD) is actively recruiting patients for this trial, which is being conducted by Januario Castro, M.D.
Memgen is a clinical stage biotechnology company dedicated to improving overall survival in cancer patients. Its technology platform is based on discoveries by leaders in the field of hematologic malignancies. Memgen is developing truly effective and non-toxic targeted therapies utilizing key elements of the human immune system engineered to generate anti-cancer immune responses. Learn more
Latest News & Events ::
6/4/2009 - ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic Leukemia
Januario Castro, M.D., delivered an oral presentation on a recent clinical trial of a single direct injection of ISF35 at the ASCO annual meeting in Orlando June 1.
12/3/2008 - Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 ASH Annual Meeting
Memgen's CLL clinical trials at UCSD and M.D. Anderson will be presented at ASH, Dec. 6-9.